Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, ...

MINNEAPOLIS, MN – September 16, 2026 – Evia Bio, Inc., a life science company advancing next-generation cryopreservation ...

September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused ...

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and ...

Connection details for the SENS-601 Program Day are as follows: Date and time: September 22, 2026, at 2:30pm CET (8:30am ET) ...

Electra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ...

Bristol Myers Squibb acquired the degrader-antibody conjugate from Orum Therapeutics in 2023 for $100 million upfront and the possibility of up to $80 million more in milestones.

A new five-year biotech plan has been released by the Chinese government, revealing ambitious goals such as achieving five blockbuster medicines on the global markets in that time.

As Xenon Pharmaceuticals announced that azetukalner has reached the FDA for focal seizures, the company also disclosed the emergence of psychosis adverse events in psychiatric trials of the drug, ...

Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social ...

Discover innovative financial strategies and expert guidance from leading bioscience finance executives at this first-ever ...

As part of its Regenerative Neurology Program, Longevity Medical Institute® is making MUSE cell therapy available to select ...